Japan's Teijin Pharma To Launch Gout Drug Uloric in Europe

Tokyo-based Teijin Pharma plans to launch gout drug Uloric (febuxostat) in European markets this fall after a March launch in the U.S. through licensee Takeda Pharmaceutical North America. The company also plans a NDA submission in Japan aiming for a 2011 domestic market launch. Billed as the first novel treatment for hyperuricemia in patients with gout in more than 40 years, the drug is expected to grow to achieve ¥100 billion in annual sales. (Click here for more - Japanese language

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By 

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.